PT-141 nasal spray is a research-only form of bremelanotide. Learn how it works, how it compares to the injection, typical side effects, and legal status.
PT-141 nasal refers to bremelanotide, a melanocortin receptor agonist, delivered as a liquid spray into the nose instead of by injection. The FDA has not approved any nasal form of this drug; the only approved bremelanotide product in the United States is Vyleesi, a 1.75 mg subcutaneous autoinjector approved in 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD). Bremelanotide is not FDA-approved in nasal form for any indication. Most products sold as a pt-141 nasal spray are labeled for research use only and are not intended for human consumption.
What PT-141 Does in the Body
Bremelanotide works in the brain, not in the blood vessels. It binds melanocortin receptors, mainly MC4R, in the central nervous system, which is why researchers describe it as a centrally acting agent rather than a vasodilator like sildenafil.
That mechanism shapes everything about how the drug is used. Because the target sits behind the blood-brain barrier, the amount of peptide that reaches the brain matters far more than the amount sprayed into the nostril. Nasal absorption bypasses the digestive tract and first-pass liver metabolism, but only a fraction of a sprayed dose ever crosses the nasal lining.
One more point about expectations: bremelanotide does not create spontaneous arousal on its own. In clinical trials, participants still needed sexual stimulation for the drug to produce a measurable effect.
PT-141 Nasal Spray vs. Injection
The pt-141 nasal spray vs injection comparison comes down to absorption, consistency, and regulatory status. Only the injection has been through FDA review, and only the injection has a validated dose.
| Feature | Nasal spray | Subcutaneous injection |
|---|---|---|
| FDA status | Not approved; sold as a research chemical | Approved as Vyleesi for premenopausal women with HSDD |
| Standard dose | No validated dose; vendor numbers vary widely | 1.75 mg, one dose per 24 hours, max 8 doses per month |
| Absorption | Variable and hard to predict | Consistent and measurable |
| Onset | Roughly 30 to 60 minutes | Roughly 30 to 60 minutes |
| Common side effects | Nausea, flushing, headache, nasal irritation | Nausea, flushing, headache, injection-site reactions |
| Purity control | Largely unknown | Regulated manufacturing |
Onset, Duration, and Dosing Realities
Most users report effects beginning 30 to 60 minutes after dosing, with the window lasting several hours. That timing is one reason people look for a nasal version at all. A small spray bottle is easy to carry and does not require a needle.
Dosing is where the nasal route gets murky. The labeled injected dose is 1.75 mg with at least 24 hours between doses and no more than eight doses per month. Published intranasal research has generally used larger milligram amounts, and gray-market sellers publish their own numbers that frequently conflict with one another. There is no standard nasal dose, and no reliable way to compare one vendor's product to another.
People searching for how to use pt-141 nasal spray usually find vendor instructions such as priming the pump, tilting the head back, and spraying once per nostril. Those directions are not clinical guidance, and they say nothing about concentration, purity, or how an individual will respond.
Side Effects and Safety Considerations
Nausea is the most frequently reported side effect of bremelanotide, appearing in roughly 40% of participants in the trials that supported the injected product. Flushing, headache, and fatigue are also common.
Other concerns worth knowing about include:
- Transient blood pressure increases after dosing
- Focal hyperpigmentation of the skin, face, or gums with repeated use
- Nasal irritation, dryness, or sneezing with spray formulations
- Unknown risks from impurities or incorrect concentration in unregulated products
Bremelanotide is contraindicated for people with uncontrolled high blood pressure or known cardiovascular disease, and it is not recommended during pregnancy. Anyone with a history of stroke or focal neurologic symptoms should avoid it. Talk with a healthcare professional before using any form of this peptide.
Legal Status and Sourcing in the United States
Vyleesi is prescription-only. A nasal bremelanotide preparation is not an FDA-approved drug at any strength, and selling it as a consumer product for human use is not permitted.
Results for pt-141 nasal spray for sale typically lead to research chemical vendors that ship lyophilized powder alongside a separate spray bottle. Purity certificates from those sellers are self-reported and rarely confirmed by an independent lab. Questions about how to make pt-141 nasal spray are common, but home reconstitution introduces sterility, concentration, and dosing errors that a licensed manufacturer would control.
Men make up a large share of the gray-market demand. Interest in a pt-141 peptide nasal spray for men is driven by anecdotal reports of improved erectile response, but the approved indication covers premenopausal women with HSDD only, and nasal use in men has not been studied in controlled trials.
The Bottom Line
PT-141 nasal is an unapproved delivery method for a peptide the FDA has only cleared as an injection. The intranasal research is thin, dosing is not standardized, and products sold online are not made for human use. If you are dealing with a sexual health concern, a clinician can walk you through the approved injectable option and whether your health history allows it.
Frequently Asked Questions
Is PT-141 nasal spray legal in the United States?
No nasal bremelanotide product is FDA-approved, so a nasal spray sold for human use is not a legal consumer product in the US. The only approved form of bremelanotide is the prescription autoinjector Vyleesi, which is dispensed by a pharmacy. Nasal products marketed online are typically sold as research chemicals and are not cleared for human consumption.
How long does PT-141 nasal spray take to work?
Most users report effects starting about 30 to 60 minutes after dosing, with the window lasting several hours. Because nasal absorption is inconsistent and no standard dose exists, timing varies from person to person. Responses also appear to require sexual stimulation rather than occurring spontaneously.
Does PT-141 nasal spray work for men?
Bremelanotide is only FDA-approved for premenopausal women with hypoactive sexual desire disorder, so any use in men is off-label. Most supporting data for men comes from injectable studies of erectile dysfunction, not nasal products. Nasal bremelanotide has not been tested in controlled trials in men, and claims about its effectiveness are not well supported.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.